Convalescent Plasma: The Century-long Therapies Leading up to COVID-19

Convalescent Plasma: The Century-long Therapies Leading up to COVID-19
Originally Broadcast: Wednesday, September 30th at 2 PM EDT

On August 23, the FDA authorized the emergency use of convalescent plasma in the treatment of hospitalized COVID-19 patients. Identifying and recruiting donors who have recovered from the COVID-19 virus and who possess the antibodies will be one of the outcomes of this webinar. Convalescent plasma is not a new therapy so to better understand its significance, our presenters will step through its evolution from breakthrough to becoming a treatment used for many viruses over the past 100-plus years. The discussion will delve into the effectiveness of using convalescent plasma as a treatment and focus on the potential risk factors that have raised questions regarding its true benefit. A deep dive into the considerations for blood product collectors will follow, including the recruitment of donors with the COVID-19 antibodies and how software is already assisting the majority of community blood centers and many hospital blood banks. Foundational to this discussion is where our current knowledge and software technologies will take us in terms of addressing future viral outbreaks. 

Learning Objectives:
After participating in this webinar, attendees will be able to:

  • Describe the evolution of convalescent plasma as a therapy in treating viruses of many types.
  • Identify the benefits and risks of convalescent plasma as a treatment.
  • Summarize the software tools used in on-demand recruitment of donors known to have the COVID-19 antibodies.


Avery W. Krouse
Senior Product Specialist
InVita Healthcare Technologies

Mike Deming
VP, Client Services
InVita Healthcare Technologies